Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa in Critically Ill Subjects
NCT00091910Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Sep 2003
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial in anemia comparing Epoetin alfa with Placebo (2 arms). Primary endpoint: Proportion of subjects requiring red blood cell (RBC) transfusion at Day 29. Started Sep 2003; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00091910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091910.